MedTrace Logo

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer

NCT00052468 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1742

Last updated 2014-06-25

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer.

PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.

Conditions

Interventions

DRUG

TCG

DRUG

TC

Sponsors & Collaborators

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    collaborator OTHER

  • GERCOR - Multidisciplinary Oncology Cooperative Group

    collaborator OTHER

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Andreas du Bois, MD, PhD · Dr. Horst-Schmidt-Kliniken

  • J. Herrstedt · Copenhagen County Herlev University Hospital

  • E. Pujade-Lauraine, MD, PhD · Hotel Dieu de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2009-07-31
Completion
2011-01-31

Countries

  • Denmark
  • France
  • Germany
  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00052468 on ClinicalTrials.gov